Coruzzi G, Gambarelli E, Bertaccini G, Timmerman H
Institute of Pharmacology, University of Parma, Italy.
Naunyn Schmiedebergs Arch Pharmacol. 1996 Mar;353(4):417-22. doi: 10.1007/BF00261438.
The cardiovascular effects of the new histamine H2 receptor agonist amthamine were studied in the anaesthetized rat, with particular reference to a possible interaction with the adrenergic system. Amthamine (0.03-3 mumol/kg i.v.) caused vasodepressor responses which were antagonized by famotidine (3 mumol/kg i.v.). At higher doses (30-100 mumol/kg i.v.), amthamine induced a modest increase in the mean arterial pressure, which was significantly enhanced by the blockade of H2 receptors and significantly reduced by the alpha 2 adrenoceptor antagonist yohimbine (1 mumol/kg i.v.). The vasopressor response to amthamine was not modified in rats pre-treated with reserpine or 6-hydroxydopamine, and was only minimally modified in adrenalectomized animals, thus suggesting a predominant interaction with postjunctional alpha 2 adrenoceptors in the vascular muscle. The H2 receptor agonist dimaprit (0.3-100 mumol/kg i.v.) caused a reduction in arterial pressure, which was antagonized by famotidine, no pressor response being unmasked. Dimaprit (0.1-30 mumol/kg i.v.) did not modify heart rate but caused a modest bradycardia at 100 mumol/kg i.v. Amthamine (1-100 mumol/kg i.v.) induced a dose-dependent tachycardia, which was only partially (approximately 20%) reduced by famotidine and was totally blocked by propranolol (0.3 mg/kg i.v.). This effect was significantly reduced in rats pre-treated with reserpine or 6-hydroxydopamine and was further reduced by cocaine, thus suggesting a tyramine-like action of amthamine. In conclusion, these data demonstrate that the H2 receptor agonist amthamine can also interact with the adrenergic system when used at doses higher than those necessary to activate H2 receptors. Whereas the increase in blood pressure induced by amthamine seems to be mainly mediated by a direct activation of postjunctional alpha 2 adrenoceptors, the increase in heart rate is predominantly due to neuronal release of catecholamines. These effects should be considered when using amthamine in cardiovascular or other studies when high doses are employed.
在麻醉大鼠中研究了新型组胺H2受体激动剂安他明的心血管效应,特别关注其与肾上腺素能系统可能的相互作用。安他明(静脉注射0.03 - 3 μmol/kg)引起血管减压反应,该反应被法莫替丁(静脉注射3 μmol/kg)拮抗。在较高剂量(静脉注射30 - 100 μmol/kg)时,安他明使平均动脉压适度升高,H2受体阻断可显著增强此效应,而α2肾上腺素能受体拮抗剂育亨宾(静脉注射1 μmol/kg)可使其显著降低。对用利血平或6 - 羟基多巴胺预处理的大鼠,安他明的升压反应未改变,在肾上腺切除的动物中也仅有轻微改变,因此提示其主要与血管平滑肌中的节后α2肾上腺素能受体相互作用。H2受体激动剂二甲普利(静脉注射0.3 - 100 μmol/kg)使动脉压降低,该反应被法莫替丁拮抗,未揭示出升压反应。二甲普利(静脉注射0.1 - 30 μmol/kg)不改变心率,但在静脉注射100 μmol/kg时引起适度心动过缓。安他明(静脉注射1 - 100 μmol/kg)引起剂量依赖性心动过速,该效应仅部分(约20%)被法莫替丁降低,而被普萘洛尔(静脉注射0.3 mg/kg)完全阻断。在用利血平或6 - 羟基多巴胺预处理的大鼠中,此效应显著降低,且被可卡因进一步降低,因此提示安他明有类似酪胺的作用。总之,这些数据表明,当以高于激活H2受体所需剂量使用时,H2受体激动剂安他明也可与肾上腺素能系统相互作用。安他明引起的血压升高似乎主要由节后α2肾上腺素能受体的直接激活介导,而心率增加主要归因于儿茶酚胺的神经元释放。在心血管或其他研究中使用高剂量安他明时应考虑这些效应。